NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Pharming Group N.V. (PHAR) Stock Analysis

Pharming Group N.V. (PHAR) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

PHAR

$9.65

−$0.10 (−1.03%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare PHAR with… →

PHAR Key Statistics

As of Oct 21, 2026
Trading
Open
$9.47
Previous Close
$9.75
Day's Range
9.45–9.73
52-Week Range
9.11–21.34
Volume
10.76K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.07
Valuation
Market Cap
$683.01M
P/E Ratio
74.23
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
147.33
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.86
EPS (ttm)Profit attributable to each share over the last twelve months.
0.13
Financials (FY)
Revenue (FY)
$376.13M+26.56%
Net Income (FY)
$2.85M
Profit marginThe share of revenue left as profit after all costs and taxes.
2.54%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
70.78M
1-Year Return
−28.89%
Dividend and dates
Avg Volume
23.18K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, PHAR closed at $9.65, −28.89% over 1 year.

Pharming Group N.V. (PHAR) has a market capitalization of $683.01M.

In fiscal 2025, PHAR reported revenue of $376.13M.

PHAR Stock Return by Calendar Year

Pharming Group N.V. (PHAR) return since Dec 2020: what $10,000 became

1 year
$10,000 $7,111
−28.89%
5 years
$10,000 $9,938
−0.62%
Since Dec 2020
$10,000 $5,778
−42.22%

If you had invested $10,000 in Pharming Group N.V. (PHAR) at the close on December 23, 2020, the earliest close on record here, it would have been worth $5,778 at the close on October 21, 2026: −42.22% in total, −8.98% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−45.39%
2025+75.56%
2024−11.94%
2023+3.63%
2022+23.38%
2021−41.16%
2020 (partial year)−9.01%

As of October 21, 2026.

PHAR Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$376.13M$2.85M0.8%
2024$297.20M−$11.84M−4.0%
2023$245.32M−$10.55M−4.3%
2022$205.62M$13.67M6.7%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$376.13M$330.63M$20.88M$2.85M0.8%
2024$297.20M$261.80M−$3.67M−$11.84M−4.0%
2023$245.32M$220.10M−$22.29M−$10.55M−4.3%
2022$205.62M$188.06M$9.86M$13.67M6.7%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

PHAR Valuation vs Biotechnology Median

Median of 608 stocks
MetricPHARBiotechnology medianvs median
P/E74.2316.604.5x the median
P/S ratio1.8613.300.1x the median
Profit margin2.54%−38.31%40.8 pts above

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Pharming Group N.V. (PHAR) is capitalised at $683.01M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 407.

Over the past 52 weeks the price has ranged from $9.11 to $21.34. The most recent close on file for PHAR is $9.65, dated October 21, 2026. That is −$0.10 (−1.03%) against the previous close. The latest close sits 5.93% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $376.13M. Against the prior fiscal year total of $297.20M, that is a change of +26.56%. The same year closed with net income of $2.85M. Profit margin runs at 2.54%. That is 40.8 percentage points above the Biotechnology median of −38.31%. Trailing earnings per share are 0.13.

Across the 4 fiscal years on file, revenue moves from $205.62M in 2022 to $376.13M in 2025. Of those 4 years, 2 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 74.23. That is 4.5 times the Biotechnology median of 16.6. The forward P/E on file is 147.33. Measured against sales, the shares trade at 1.86 times revenue. On price-to-sales that is 0.1 times the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 0.07. Annualized volatility over the trailing 5 years is 70.5%. Over the trailing twelve months the total return is −28.89%. Measured over 5 years, that is −0.12% a year compounded.

Growth & Income

The record shows no dividend for PHAR.

Across the complete calendar years on file, 2025 returned +75.56% and 2021 returned −41.16%. Of the 5 complete calendar years on file, 3 finished higher. 2026 is still running; the total return is −45.39% year to date.

Peer Comparison

Pharming Group N.V. (PHAR) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Pharming Group N.V. PHAR $683.01M 74.2
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Pharming Group N.V. trades at a P/E of 74.2.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Pharming Group N.V.

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3K? inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

Visit website →